- Home
- STGW vs ANAB Comparison
STGW vs ANAB Comparison
Compare STGW & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- ANAB
- Stock Information
- Founded
- STGW 1980
- ANAB 2005
- Country
- STGW United States
- ANAB United States
- Employees
- STGW N/A
- ANAB N/A
- Industry
- STGW
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- ANAB Health Care
- Exchange
- STGW Nasdaq
- ANAB Nasdaq
- Market Cap
- STGW 683.2M
- ANAB 759.5M
- IPO Year
- STGW N/A
- ANAB 2017
- Fundamental
- Price
- STGW $4.46
- ANAB $22.23
- Analyst Decision
- STGW Buy
- ANAB Buy
- Analyst Count
- STGW 5
- ANAB 10
- Target Price
- STGW $8.60
- ANAB $42.25
- AVG Volume (30 Days)
- STGW 1.3M
- ANAB 545.9K
- Earning Date
- STGW 05-08-2025
- ANAB 05-05-2025
- Dividend Yield
- STGW N/A
- ANAB N/A
- EPS Growth
- STGW N/A
- ANAB N/A
- EPS
- STGW N/A
- ANAB N/A
- Revenue
- STGW $2,822,897,000.00
- ANAB $111,872,000.00
- Revenue This Year
- STGW $4.99
- ANAB N/A
- Revenue Next Year
- STGW $8.11
- ANAB $9.72
- P/E Ratio
- STGW N/A
- ANAB N/A
- Revenue Growth
- STGW 9.64
- ANAB 387.20
- 52 Week Low
- STGW $4.46
- ANAB $12.21
- 52 Week High
- STGW $8.18
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- STGW 33.20
- ANAB 62.32
- Support Level
- STGW $4.66
- ANAB $20.50
- Resistance Level
- STGW $5.08
- ANAB $22.84
- Average True Range (ATR)
- STGW 0.24
- ANAB 1.28
- MACD
- STGW -0.05
- ANAB 0.12
- Stochastic Oscillator
- STGW 0.83
- ANAB 83.24
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).